8 completed, 7 recruiting, 4 terminated, 4 unknown. 7 Phase 2, 6 Phase 1, 3 Not applicable, 3 Phase 3, 2 Phase 4.
Follow BK Virus Infection: new trials by email Literature Review of BK Virus Infection trials Research Report on BK Virus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 25BT056: Basket Study of Viral Cytotoxic T Lymphocytes Virus-Specific Cytotoxic T Lymphocytes (vCTLs) - EBV Viremia, CMV Viremia | Early Phase 1 | Not yet recruiting | Children's Hospital of Philadelphia | 35 | 2026-11-01 | 2026-10-22 |
| A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection AIC263029, Placebo - BK Virus Infection, BKV Infection | Phase 2 | Recruiting | AiCuris Anti-infective Cures AG | 24 | 2026-10-05 | 2026-10-23 |
| ID-ENTITY Trial- Evaluating Serial T-ID Monitoring Blood tests, TRAC( cell free DNA) and T-ID - Kidney Diseases, Kidney Injury | Enrolling by invitation | Transplant Genomics, Inc. | 1000 | 2026-05-19 | 2026-10-06 | |
| Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy Nephropathy, Opportunistic Viral Infection | Recruiting | University Hospital, Grenoble | 100 | 2026-03-11 | 2026-05-27 | |
| R-MVST Cells for Treatment of Viral Infections in Children and Young Adults Rapidly generated virus specific T (R-MVST) cells - Epstein-Barr Virus, Cytomegalovirus Infections | Phase 1 | Recruiting | Monica Bhatia | 18 | 2025-04-20 | 2026-07-30 |
| Immune Registry for BK in Kidney Transplant Recipients Blood samples: Main Study group, Data Collection, Urine Sample- Main Study group - BK Virus Infection, Kidney Transplant; Complications | Recruiting | Virginia Commonwealth University | 60 | 2024-05-29 | 2026-08-20 | |
| The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient Everolimus, reduced dose tacrolimus and Leflunomide - Kidney Transplant Infection, BK Virus Infection | Not applicable | Active not recruiting | King Chulalongkorn Memorial Hospital | 50 | 2023-06-15 | 2026-05-28 |
| Prediction of BK Virus Reactivation in Kidney Transplant Recipient BKV immune monitoring - Kidney Transplant Infection, BK Virus Infection | Not applicable | Completed | King Chulalongkorn Memorial Hospital | 80 | 2023-05-01 | 2025-12-31 |
| Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients Virus-specific Cytotoxic T-lymphocytes - Adenovirus Infection, BK Virus Infection | Phase 1 | Terminated | M.D. Anderson Cancer Center | 12 | 2023-01-06 | 2026-08-11 |
| Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation Brincidofovir - BK Virus Infection, Nephropathy | Phase 2 | Terminated | SymBio Pharmaceuticals | 1 | 2022-10-14 | 2024-12-04 |
| New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies BK Virus Infection | Recruiting | University Hospital, Strasbourg, France | 100 | 2022-09-05 | 2025-08-08 | |
| R-MVST Cells for Treatment of Viral Infections Rapidly generated virus specific T (R-MVST) cells - Epstein-Barr Virus Infections, Cytomegalovirus Infections | Phase 1 | Recruiting | Columbia University | 36 | 2022-05-03 | 2026-06-10 |
| Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Posoleucel (ALVR105), Placebo - Adenovirus Infection, BK Virus Infection | Phase 2 / Phase 3 | Terminated | AlloVir | 451 | 2022-03-24 | 2024-05-16 |
| BK With VST for Kidney Transplant Patients BK-specific T cells from Donor Lymphocytes - Kidney Transplant Infection, BK Virus Infection | Phase 1 | Completed | University of Wisconsin, Madison | 3 | 2021-12-16 | 2024-12-10 |
| Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia Blood sample - BK Virus Infection, Nephropathy | Unknown | Assistance Publique - Hôpitaux de Paris | 41 | 2021-09-02 | 2024-04-03 | |
| Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia Posoleucel (formerly known as ALVR105) cells, Placebo (visually identical to Posoleucel) - BK Virus Nephropathy, BK Virus Infection | Phase 2 | Completed | AlloVir | 61 | 2021-03-22 | 2024-05-16 |
| Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) Posoleucel (ALVR105), Placebo - BK Virus Infection, Hemorrhagic Cystitis | Phase 3 | Terminated | AlloVir | 97 | 2021-03-18 | 2024-05-14 |
| Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Posoleucel (ALVR105) - Adenovirus Infection, BK Virus Infection | Phase 2 / Phase 3 | Completed | AlloVir | 26 | 2021-01-15 | 2024-05-09 |
| A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients MAU868, Placebo - BK Virus Infection | Phase 2 | Completed | Vera Therapeutics, Inc. | 30 | 2020-08-05 | 2023-06-07 |
| Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS BK Virus Infection | Unknown | University Hospital, Strasbourg, France | 100 | 2020-01-01 | 2022-11-16 |
Showing 20 of 29. Sign in to see all of them.
Adenoviridae Infections (7) · Cytomegalovirus Infections (7) · Epstein-Barr Virus Infections (6) · Kidney Diseases (4) · Virus Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Merkel Cell (1) · Cystitis, Hemorrhagic (1) · Encephalitis, Viral (1) · Hematologic Neoplasms (1) · Immunologic Deficiency Syndromes (1) · Neoplasms (1) · Primary Immunodeficiency Diseases (1) · Severe Combined Immunodeficiency (1) · Viremia (1)
Infections (10) · DNA Virus Infections (9) · Herpesviridae Infections (8) · Virus Diseases (8) · Tumor Virus Infections (7) · Urogenital Diseases (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Urologic Diseases (5) · Immune System Diseases (3) · Immunologic Deficiency Syndromes (2) · Adenocarcinoma (1) · Blood-Borne Infections (1) · Brain Diseases (1)
Cell Count (3) · Everolimus (2) · Leflunomide (2) · Blood Specimen Collection (1) · Ciprofloxacin (1) · Data Collection (1) · Hematologic Tests (1) · Mycophenolic Acid (1) · brincidofovir (1)
AlloVir (5) · King Chulalongkorn Memorial Hospital (2) · M.D. Anderson Cancer Center (2) · University Hospital, Strasbourg, France (2) · AiCuris Anti-infective Cures AG (1) · Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · Children's Hospital of Philadelphia (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Karolinska University Hospital (1) · Loma Linda University (1) · Monica Bhatia (1) · SL VAXiGEN (1) · SymBio Pharmaceuticals (1)
United States (18) · France (6) · South Korea (3) · Canada (2) · Italy (2) · Spain (2) · Sweden (2) · Thailand (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Japan (1) · Turkey (Türkiye) (1)
Ahmed O Gaber, MD (1) · Allison Webber, MD (1) · Ambreen Azhar (1) · Amir Abdipour, MD (1) · Bilal Omer, MD (1) · Caitlin Elgarten, MD, MSCE (1) · George Chen, MD (1) · Jacques Galipeau, MD (1) · Jerome Ritz, MD (1) · John Craddock, MD (1) · Lars Wennberg, MD, PhD (1) · May Daher, MD (1) · Monica Bhatia, MD (1)
PMID 39382091, PMID 38597860, PMID 30304652, PMID 30811872, PMID 32463180, PMID 33929874, PMID 38593233, PMID 39352862, PMID 40249038, PMID 40828617, PMID 42402341